体外膜肺氧合对抗真菌药物药动学的影响  

Effect of Extracorporeal Membrane Pulmonary Oxygenation on Pharmacokinetics of Antifungal Drugs

作　　者：柳熠鑫 李珊 任菲菲 张志清[1] LIU Yixin;LI Shan;REN Feifei;ZHANG Zhiqing(Department of Pharmacy,the Second Hospital of Hebei Medical University,Shijiazhuang 050000,China)

机构地区：[1]河北医科大学第二医院药学部,石家庄050000

出　　处：《医药导报》2022年第10期1480-1485,共6页Herald of Medicine

基　　金：河北省自然科学基金资助项目(H2021206384)。

摘　　要：体外膜肺氧合(ECMO)是一种体外循环装置,用于支持顽固性呼吸和(或)心力衰竭患者,延长其心肺功能时间。接受ECMO的通常是重症监护病房(ICU)中病情严重患者,由于经常应用广谱抗菌药物、免疫系统受损以及接受插管等原因,容易受到真菌的侵袭和感染。临床上常用的抗真菌药物种类繁多,而ECMO很容易对药物的药动学(PK)产生影响。该文就ECMO对抗真菌药物PK的影响进行讨论,为合并真菌感染ECMO患者的抗真菌治疗提供参考。Extracorporeal membrane pulmonary oxygenation(ECMO)is a cardiopulmonary bypass device used for patients with persistent respiratory and cardiac failure to extend time of cardiopulmonary support.Patients receiving ECMO usually are critically ill patients in ICU.Because of the frequent use of broad-spectrum antibiotics,compromised immune systems,and intubation,ECMO recipients are more vulnerable to be attacked by fungal invasion.Many kinds of antifungals are commonly used in clinic,and most are concentration-dependent drugs;the pharmacokinetics of those drugs is easily affected by ECMO.This article discusses the effect of ECMO on pharmacokinetics of antifungal drug,and hopes to provide a reference for the antifungal treatment for ECMO patients with fungal infection.

关 键 词：体外膜肺氧合 抗真菌药物 药动学 

分 类 号：R978.5[医药卫生—药品]